Prognostic factors in advanced renal cell cancer

Camillo Porta, Ilaria Imarisio, Chiara Paglino, Elisa Ferraris, Mario Mensi, Bruno Rovereto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The identification of reliable and reproducible prognostic factors (defined as those factors that define the risk of death, or of recurrence, independently of therapy) in advanced renal cell carcinoma patients has became a priority in this field. To date, the Memorial Sloan Kettering Cancer Center - or Motzer's - criteria are those more commonly used, especially within clinical trials, but their role in the era of molecularly-targeted therapies is challenged. Molecular and genetic factors are currently being studied - with still conflicting results -, trying to incorporate them into presently available score systems and algorithms. The next generation of prognostic tools will probably include both genomic and proteomic techniques.

Original languageEnglish
Pages (from-to)35-37
Number of pages3
JournalEuropean Journal of Cancer, Supplement
Volume6
Issue number14
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Renal Cell Carcinoma
Proteomics
Molecular Biology
Clinical Trials
Recurrence
Therapeutics
Neoplasms

Keywords

  • Kidney cancer
  • Metastatic disease
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic factors in advanced renal cell cancer. / Porta, Camillo; Imarisio, Ilaria; Paglino, Chiara; Ferraris, Elisa; Mensi, Mario; Rovereto, Bruno.

In: European Journal of Cancer, Supplement, Vol. 6, No. 14, 10.2008, p. 35-37.

Research output: Contribution to journalArticle

@article{e9c3cc528aa446ee92af5952ad1df739,
title = "Prognostic factors in advanced renal cell cancer",
abstract = "The identification of reliable and reproducible prognostic factors (defined as those factors that define the risk of death, or of recurrence, independently of therapy) in advanced renal cell carcinoma patients has became a priority in this field. To date, the Memorial Sloan Kettering Cancer Center - or Motzer's - criteria are those more commonly used, especially within clinical trials, but their role in the era of molecularly-targeted therapies is challenged. Molecular and genetic factors are currently being studied - with still conflicting results -, trying to incorporate them into presently available score systems and algorithms. The next generation of prognostic tools will probably include both genomic and proteomic techniques.",
keywords = "Kidney cancer, Metastatic disease, Prognostic factors",
author = "Camillo Porta and Ilaria Imarisio and Chiara Paglino and Elisa Ferraris and Mario Mensi and Bruno Rovereto",
year = "2008",
month = "10",
doi = "10.1016/j.ejcsup.2008.06.009",
language = "English",
volume = "6",
pages = "35--37",
journal = "European Journal of Cancer, Supplement",
issn = "1359-6349",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Prognostic factors in advanced renal cell cancer

AU - Porta, Camillo

AU - Imarisio, Ilaria

AU - Paglino, Chiara

AU - Ferraris, Elisa

AU - Mensi, Mario

AU - Rovereto, Bruno

PY - 2008/10

Y1 - 2008/10

N2 - The identification of reliable and reproducible prognostic factors (defined as those factors that define the risk of death, or of recurrence, independently of therapy) in advanced renal cell carcinoma patients has became a priority in this field. To date, the Memorial Sloan Kettering Cancer Center - or Motzer's - criteria are those more commonly used, especially within clinical trials, but their role in the era of molecularly-targeted therapies is challenged. Molecular and genetic factors are currently being studied - with still conflicting results -, trying to incorporate them into presently available score systems and algorithms. The next generation of prognostic tools will probably include both genomic and proteomic techniques.

AB - The identification of reliable and reproducible prognostic factors (defined as those factors that define the risk of death, or of recurrence, independently of therapy) in advanced renal cell carcinoma patients has became a priority in this field. To date, the Memorial Sloan Kettering Cancer Center - or Motzer's - criteria are those more commonly used, especially within clinical trials, but their role in the era of molecularly-targeted therapies is challenged. Molecular and genetic factors are currently being studied - with still conflicting results -, trying to incorporate them into presently available score systems and algorithms. The next generation of prognostic tools will probably include both genomic and proteomic techniques.

KW - Kidney cancer

KW - Metastatic disease

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=55649094887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649094887&partnerID=8YFLogxK

U2 - 10.1016/j.ejcsup.2008.06.009

DO - 10.1016/j.ejcsup.2008.06.009

M3 - Article

AN - SCOPUS:55649094887

VL - 6

SP - 35

EP - 37

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 1359-6349

IS - 14

ER -